Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dementia MCI (Mild Cognitive Impairment) Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

NCT02614131
View directory record Official record
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 24, 2026, 1:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

NCT04928976
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 24, 2026, 1:45 AM EDT
Active, not recruiting Not applicable Interventional

Multi-Center Study of Sensory Stimulation to Improve Brain Function

NCT03556280
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers, Dementia, Mild, Dementia, Alzheimer Type, Dementia of Alzheimer Type, Dementia, Cognitive Impairment, Mild, Cognitive Decline
Interventions
GammaSense Stimulation System (Active Settings), GammaSense Stimulation System (Sham Settings)
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Delray Beach, Florida • Stuart, Florida • Methuen, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Not applicable Interventional Results available

Improvisational Movement for People With Memory Loss and Their Caregivers

NCT03333837
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia, Mild Cognitive Impairment
Interventions
Dance Group, Non-Group Dance, Social Group, No Contact
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 85 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Jul 24, 2026, 1:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

NCT05904132
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
tACS device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 24, 2026, 1:45 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

NCT06254469
View directory record Official record
Conditions
Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions
[F-18]Flornaptitril
Drug
Lead sponsor
CereMark Pharma, LLC
Industry
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 24, 2026, 1:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Brain Aging in Vietnam War Veterans

NCT01687153
View directory record Official record
Conditions
Traumatic Brain Injury, Post Traumatic Stress Disorder, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 90 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
19
States / cities
Sun City, Arizona • Irvine, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2021 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Music, Sleep and Dementia Study

NCT04157244
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Tailored music listening intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults

NCT04480112
View directory record Official record
Conditions
Memory Disorders, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Technology based social interactions, No research related technology based social interactions
Behavioral · Other
Lead sponsor
Boston University
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables

NCT05159557
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System, Limited In-Home Technology
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 24, 2026, 1:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

NCT05107882
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Interventions
Not listed
Lead sponsor
Optina Diagnostics Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Las Vegas, Nevada • Norfolk, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Phase 4 Interventional Results available

Cognitive Decline in Non-demented PD

NCT01340885
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Strattera, Exelon, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

NCT04867616
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Bepranemab
Other · Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
50 Years to 80 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Fresno, California • Fullerton, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jul 24, 2026, 1:45 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Epileptic Hippocampus in Alzheimer's Disease

NCT05899764
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Brivaracetam
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment

NCT01605448
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Mindfulness Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 24, 2026, 1:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

NCT02266563
View directory record Official record
Conditions
Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment
Interventions
Amyvid PET Scan, T807 PET scan
Drug
Lead sponsor
Samuel Gandy
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Jul 24, 2026, 1:45 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Alzheimer's Disease

NCT02831283
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional)
Drug · Procedure
Lead sponsor
Patrick Lao
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jul 24, 2026, 1:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

NCT03372317
View directory record Official record
Conditions
Mild Cognitive Impairment, Aging
Interventions
18F-MK-6240
Drug
Lead sponsor
Yaakov Stern
Other
Eligibility
55 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Not applicable Interventional Results available

Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment

NCT02155946
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 88 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

NCT02423200
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VX-745
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Jul 24, 2026, 1:45 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Mid-frontal Delta/Theta and Cognitive Control

NCT06984757
View directory record Official record
Conditions
Parkinson&Amp;Amp;#39;s Disease (PD)
Interventions
Deep-brain Stimulation, Transcranial Magnetic Stimulation, Transcranial Alternating Current Stimulation
Device
Lead sponsor
Nandakumar Narayanan
Other
Eligibility
18 Years to 99 Years
Enrollment
635 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 24, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

NCT02502253
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
grape seed polyphenolic extract, resveratrol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 24, 2026, 1:45 AM EDT